Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 44.77 as of 2026-09-12T00:15:35.677Z.
Consensus retrieved: 2026-09-11T02:34:14.577Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-12T00:15:35.677Z.
Quote observation: 2026-09-11T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ddd63485a43e27ae5d23ef79ae4ae0a88e1f84f529dfa76bd2161c08446e3651
Forward PE Ratio (44.77) = Dated Quote Price ($409.85) / Consensus Forward EPS ($9.15)
FORWARD PE RATIO
44.77
SECTOR MEDIAN · HEALTHCARE
18.95
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+136.19%
vs the sector median at left
Humana Inc.
Market Cap
$49.21B
Forward PE Ratio
44.77
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Humana Inc. (HUM) | $49.21B | 44.77 |
| Becton, Dickinson and Company (BDX)vs › | $49.00B | 14.04 |
| Edwards Lifesciences Corporation (EW)vs › | $48.58B | 28.11 |
| Cardinal Health, Inc. (CAH)vs › | $54.94B | 18.70 |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $43.20B | 18.72 |
| IQVIA Holdings Inc. (IQV)vs › | $43.09B | 20.19 |
| Agilent Technologies, Inc. (A)vs › | $41.50B | 23.69 |
| Moderna, Inc. (MRNA)vs › | $57.13B | N/A |
| IDEXX Laboratories, Inc. (IDXX)vs › | $39.81B | 34.17 |
| Cencora, Inc. (COR)vs › | $62.57B | 17.99 |
Trailing P/E
38.8
reported TTM EPS
Forward P/E
44.8
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $9.15 implies -13.4% EPS decline vs the reported trailing $10.56.
At the dated quote price of $409.85, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $9.15 | $9.03 – $9.61 | 16 | 44.8x |
| 2027-12-31 | $16.72 | $11.38 – $19.84 | 16 | 24.5x |
| 2028-12-31 | $27.70 | $19.76 – $33.50 | 8 | 14.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
